Navigation Links
ThermoGenesis Corp. and TotipotentSC Receive Approval for Phase Ib Clinical Trial of Res-Q™ 60 BMC for Treatment of Critical Limb Ischemia
Date:1/26/2011

RANCHO CORDOVA, Calif., Jan. 26, 2011 /PRNewswire/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, and TotipotentSC, a U.S. company with a large India presence in medical devices, cellular therapy and clinical research management, announced today they have received approval from Fortis Escorts' (New Delhi) Independent Ethics Committee to proceed with a Phase Ib clinical trial in patients suffering from Non-Reconstructable Critical Limb Ischemia (CLI) utilizing ThermoGenesis' Res-Q™ 60 BMC system.

CLI, an advanced stage of peripheral artery disease, is characterized by peripheral arterial obstruction resulting in a severe reduction in blood flow to the extremities (hands, feet and legs).  This chronic vascular disorder presents symptoms progressing from mild discomfort to severe rest pain, skin ulcers and major tissue death.  CLI may result in limb amputation if not properly treated.  CLI afflicts millions of patients globally, and has a significant impact in the Indian population.  As such, CLI is a heavy burden on the Indian healthcare system with an estimated 20 million patients suffering from various stages of the disease.

The objectives of the trial are to assess safety and efficacy of stem cells derived from autologous concentrated bone marrow prepared using the Res-Q system.  Specific primary endpoints include safety of the cell processing and delivery plus limb salvage rates in 15 patients suffering from the most advanced stage of peripheral artery disease.  Each enrolled patient will have been determined medically unsuitable for further traditional modalities of treatment.  

The Res-Q system is CE-Marked for Europe and is an exempt Class I device in the U.S. as a laboratory single use sterile (disposable) bone marrow concentrati
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThermoGenesis Corp. Files Shelf Registration Statement on Form S-3
2. ThermoGenesis Signs Major Bone Marrow Product Distribution Agreement in China
3. ThermoGenesis Reports 35 Percent Increase in First Quarter 2011 Revenues, Adds Strategic Advisor and Inks China Distribution Deal With Nanshan Memorial Medical Institute
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2011 Results on November 4, 2010
5. ThermoGenesis Announces Platelet Rich Plasma (PRP) Res-Q Cardiovascular Licensing Agreement
6. ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000
7. ThermoGenesis Regains Compliance With NASDAQ Listing Rules
8. ThermoGenesis Announces Reverse Stock Split Effective on NASDAQ Capital Market August 27, 2010
9. ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program
10. ThermoGenesis Names Jorge Artiles Vice President, Chief Quality and Regulatory Affairs Officer
11. ThermoGenesis Announces National Institute of Health Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 2015 EUSA Pharma (EUSA), a ... announced the appointment of Lee Morley as ... Non-Executive Director.  Bryan Morton, who established EUSA Pharma as ... Lee Morley joins from Jazz ... of Commercial for Europe and ...
(Date:4/20/2015)... KUALA LUMPUR, Malaysia , April 20, 2015 /PRNewswire/ ... 2015, resulting in a scarcity of opportunities for generic ... drug manufacturers in the region are looking beyond the ... the quality of existing drugs. Certain established generic manufacturers ... research and development of new molecules, although the impact ...
(Date:4/20/2015)... , April 20, 2015 This report analyzes the ... following Product Segments: Non-Powered Breast Pumps, and Powered Breast Pumps. ... Canada , Japan , ... Rest of World. Annual estimates and forecasts are provided for ... is provided for these markets. Market data and analytics are ...
Breaking Medicine Technology:EUSA Pharma Appoints Lee Morley as Chief Executive and Industry Veteran Göran Ando to Board of Directors 2EUSA Pharma Appoints Lee Morley as Chief Executive and Industry Veteran Göran Ando to Board of Directors 3Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 2Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 3Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 4Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 5World Breast Pumps Industry 2World Breast Pumps Industry 3World Breast Pumps Industry 4World Breast Pumps Industry 5World Breast Pumps Industry 6World Breast Pumps Industry 7World Breast Pumps Industry 8World Breast Pumps Industry 9World Breast Pumps Industry 10World Breast Pumps Industry 11World Breast Pumps Industry 12World Breast Pumps Industry 13World Breast Pumps Industry 14
... NEW YORK, Oct. 6 Reportlinker.com announces ... available in its catalogue. , ... Pharma and Biotech , ... The Drug Delivery Partnering Agreements in Pharma ...
... N.J., Oct. 6 Centocor Ortho Biotech Inc. and ... the European Commission has approved SIMPONI(TM) (golimumab) as a ... rheumatoid arthritis (RA), active and progressive psoriatic arthritis (PsA) ... In the European Union, SIMPONI is approved as a ...
Cached Medicine Technology:Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech 2Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech 3Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech 4Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech 5Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech 6Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech 7SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 2SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 3SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 4SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 5SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 6SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 7SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 8SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 9SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 10
(Date:4/21/2015)... April 21, 2015 Zane Benefits, a ... today its CEO Rick Lindquist has been selected as ... , According to Rick Lindquist, “There is a massive ... Zane Benefits’ small business solutions are at its forefront. ... by Employee Benefit Adviser’s Rising Stars.” , According to ...
(Date:4/21/2015)... Carinsuranceshoppingsource.com has released a new blog post explaining how ... vehicles. , Eco-friendly cars can be important for ... Some insurance agencies may even offer generous discounts for ... clients should consider the costs of auto insurance premiums. ... cost more to insure. Eco-friendly vehicles however, may be ...
(Date:4/21/2015)... Carinsurancesavings.biz has released a new blog post ... and explaining the impact on a uto insurance prices ... supervised may be eligible for advantageous auto insurance discounts. Clients ... and efficient way. This will also help them get the ... way. , Finding low cost coverage is no longer difficult ...
(Date:4/21/2015)... April 21, 2015 Let's face it; a ... through fancy products and complex routines for hundreds of dollars. ... through suncare, not gimmicks, as the sun is the leading ... good suncare is more than just daily sun protection; it ... Block Island Organics’ new Purifying Facial Cleanser and ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Optimity ... Information Technology advisory firm that helps clients in ... today announced that the Association of Community ... Preferred Vendor. ACAP represents 58 local, not-for-profit, community-affiliated ... than 13 million people primarily enrolled in public ...
Breaking Medicine News(10 mins):Health News:Zane Benefits’ CEO Named Top 20 Rising Stars 2Health News:Auto Insurance Quotes For Eco-Friendly Vehicles 2Health News:Auto Insurance Quotes Offer Excellent Security for A Car 2Health News:Block Island Organics Debunks Skin Care Myths with New Products 2Health News:Block Island Organics Debunks Skin Care Myths with New Products 3Health News:Optimity Advisors Named Preferred Vendor by the Association of Community Affiliated Plans (ACAP) 2
... are, the more accurate a picture you get when you ... ability to simultaneously measure as many as 100 or more ... disease such as cancer, that capability would provide a much ... , A Stanford University School of Medicine team led by ...
... Industries, Inc. ( www.sanitecindustries.com ),the global patent holder ... Disinfection System(TM), has successfully emerged from its Chapter ... for the Central District of California ruled yesterday ... Industries should be confirmed thus clearing the way ...
... has successfully implemented TransportConnect(TM) at Intuitive Surgical ... DGN Technologies, Inc. announced today that ... Surgical, located in Sunnyvale, California, USA. ... and selected TransportConnect(TM) to address the specific ...
... got milk? Milk Mustache,Mobile Drink Well. Live Well. Tour ... and its array of benefits. The Tour,cruised through Atlanta ... only live well but to drink well with nature,s ... little face of wellness!...Luciano Liberona was very excited to ...
... could reduce related blindness by almost 35%, study suggests, ... rate of age-related macular degeneration is on the increase, ... of the disease by about 35 percent, new estimates ... Centers for Disease Control and Prevention, researchers report that ...
... of Transplantation Joins James Redford on May 30 ... to Raise Transplant Awareness BOSTON, April ... the American Society of Transplantation (AST) will host Share the ... benefit organ donation awareness and transplant research . Share the ...
Cached Medicine News:Health News:Stanford researchers harness nanoparticles to track cancer-cell changes 2Health News:Stanford researchers harness nanoparticles to track cancer-cell changes 3Health News:Sanitec Industries Emerges From Chapter 11 2Health News:DGN Technologies TransportConnect(TM) Successfully Implemented at Intuitive Surgical 2Health News:DGN Technologies TransportConnect(TM) Successfully Implemented at Intuitive Surgical 3Health News:The Hispanic Got Milk? Campaign Recently Visited Atlanta Promoting the Drink Well. Live Well. Tour! 2Health News:Nearly 18 Million Will Have Macular Degeneration by 2050 2Health News:Nearly 18 Million Will Have Macular Degeneration by 2050 3Health News:Country Star Phil Vassar to Perform at Transplantation Fundraiser 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: